Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo

D Reglodi, P Kiss, A Lubics… - Current pharmaceutical …, 2011 - ingentaconnect.com
Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and
multifunctional peptide exerting its effects via 3 main receptors (PAC1, VPAC1 and VPAC2) …

VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies

TW Moody, T Ito, N Osefo… - Current Opinion in …, 2011 - journals.lww.com
PACAP/VIP as well as their three classes of receptors are important in many physiological/
pathophysiological processes, some of which are identified in these studies using knockout …

Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide

DE Brenneman - Peptides, 2007 - Elsevier
The neuroprotective properties of vasoactive intestinal peptide (VIP) and pituitary adenylate
cyclase-activating polypeptide (PACAP) place these peptides in a special category of …

Protective effects of pituitary adenylate cyclase activating polypeptide against neurotoxic agents

D Reglodi, A Tamas, A Jungling, A Vaczy, A Rivnyak… - Neurotoxicology, 2018 - Elsevier
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide highly
expressed in the central and peripheral nervous system, where it exerts several …

PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity

TS Guillot, JR Richardson, MZ Wang, YJ Li, TN Taylor… - Neuropeptides, 2008 - Elsevier
Pituitary adenylyl cyclase activating polypeptide, 38 amino acids (PACAP38) is a brain-gut
peptide with diverse physiological functions and is neuroprotective in several models of …

[HTML][HTML] Pituitary adenylate cyclase-activating polypeptide: a promising neuroprotective peptide in stroke

Y Fang, R Ren, H Shi, L Huang, C Lenahan… - Aging and …, 2020 - ncbi.nlm.nih.gov
The search for viable, effective treatments for acute stroke continues to be a global priority
due to the high mortality and morbidity. Current therapeutic treatments have limited effects …

Protective effects of PACAP in the retina

T Atlasz, A Vaczy, D Werling, P Kiss, A Tamas… - Pituitary adenylate …, 2016 - Springer
Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread neuropeptide
that is well known for its general cytoprotective effects in different neuronal injuries, such as …

Alternative routes of administration of the neuroprotective pituitary adenylate cyclase activating polypeptide

D Reglodi, T Atlasz, A Jungling, E Szabo… - Current …, 2018 - ingentaconnect.com
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with diverse
actions, including strong neurotrophic and neuroprotective effects. The aim of our present …

Diabetes affects the pituitary adenylate cyclase-activating polypeptide (PACAP)-like immunoreactive enteric neurons in the porcine digestive tract

K Palus, M Bulc, J Całka, Ł Zielonka… - International Journal of …, 2021 - mdpi.com
Diabetic gastroenteropathy is a common complication, which develops in patients with long-
term diabetes. The pituitary adenylate cyclase-activating polypeptide (PACAP) is a …

[PDF][PDF] A PACAP neuroprotektív és általános citoprotektív hatásainak vizsgálata in vitro és in vivo modellekben

D Reglődi - 2009 - real-d.mtak.hu
I. 1. Hypophysis adenilát-cikláz aktiváló polipeptid (PACAP) 5 I. 2. A PACAP előfordulása a
szervezetben 6 I. 3. A PACAP-receptorok és előfordulásuk a szervezetben 6 I. 4. A PACAP …